enGene Therapeutics Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 22/100
What the filing says
enGene Therapeutics held a virtual Key Opinion Leader (KOL) event on August 11, 2026, presenting market research on non-muscle invasive bladder cancer (NMIBC) and its investigational lead program detalimogene voraplasmid. The company shared market insights based on 65 urologist interviews, 15 payer interviews, 2,000 patient claims, and clinical literature. Detalimogene is a non-viral gene therapy in Phase 2 development (LEGEND study) with a pivotal cohort expecting 12-month data and BLA filing in 2H 2026; the company has $285M in cash. The presentation projects a BCG-unresponsive NMIBC addressable patient pool of ~21,600 patients annually with potential sequencing effects, and benchmarks pricing at ~$650K–$700K per patient per year.
Why this rating
KOL presentation with market research is routine investor communication; no material corporate action, financial restatement, deal, or regulatory outcome disclosed. Event is small relative to company scale.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.